Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed

Akari Therapeutics Plc

All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.
Transaction expected to close on November 13, 2024.
Upon close, Akari expects to remedy Nasdaq shareholder deficiency, removing delisting risk.
All-stock merger structured for ~50/50 ownership between Akari and Peak Bio holders.
Combined entity to operate as Akari Therapeutics, trading as AKTX on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.